GlaxoSmithKline took its second hit in the space of a few days as a US Senate committee suggested its diabetes medicine Avandia may increase the risk of a heart attack. Brokers reckon the main risk to the company is from possible litigation as the report claims that Glaxo knew of possible heart attack risks related to the medication years before the evidence became public.Foreign exchange tailwinds enabled outsourcing and distribution group Bunzl to boost 2009 profits, sending it to the top of the FTSE 100 risers. Profit before tax in 2009 rose 6% to £257.8m from £242.9m in 2008, but was down 5% in constant currency terms.Swiss broker UBS is more bullish on Lloyds than Royal Bank of Scotland, rating the shares a 'buy' ahead of Friday's results. The UBS banking team thinks that impairment charges will have topped out in the first half of 2009, and is expecting second half impairments to be 23% lower than the first half at £10.3bn.'While funding will remain a source of market debate on Lloyds, in our view, the group should be a near-term beneficiary of two key trends: asset re-pricing and an improvement in liability costs,' UBS suggests. FTSE 100 - RisersBunzl (BNZL) 679.00p +3.98%Royal Bank of Scotland Group (RBS) 35.57p +3.01%Vedanta Resources (VED) 2,630.00p +2.98%Kazakhmys (KAZ) 1,371.00p +2.70%Lloyds Banking Group (LLOY) 51.83p +2.59%Eurasian Natural Resources (ENRC) 1,059.00p +2.42%Rio Tinto (RIO) 3,492.50p +2.30%Old Mutual (OML) 111.00p +2.30%FTSE 100 - FallersGlaxoSmithKline (GSK) 1,207.00p -2.27%Marks & Spencer Group (MKS) 336.00p -1.87%Next (NXT) 1,912.00p -1.49%Thomas Cook Group (TCG) 237.80p -1.41%London Stock Exchange Group (LSE) 656.00p -1.35%Shire Plc (SHP) 1,356.00p -1.02%British American Tobacco (BATS) 2,203.00p -0.99%Compass Group (CPG) 475.70p -0.90%